
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

# NCI Director's Update

**Dr. John E. Niederhuber** Director, National Cancer Institute


Board of Scientific Advisors June 28, 2010



# Applications for 2011

- FY11 President's Budget estimate (without ARRA bump)
  - 1,220 competing RPG awards
  - ~7,300 estimated applications
  - 16.8% success rate
- Estimating ARRA bump in applications
  - 400 GO and Challenge Grants unfunded
  - -<u>106 ARRA</u> 2-year R01s funded
  - ~7,800 possible applications (†~500)
  - 15.7 % success rate

### NCI FY 2010 Budget by Mechanism



Preparing for the Fourth Quarter of FY 2010

- FY 2010 is on track to close out, as expected without major issues
  - -Approaching the fourth quarter, about 60 percent of the NCI research budget has been obligated
    - This is slightly ahead of where we were at this time last year

### Preparing for the Fourth Quarter of FY 2010

#### • FY 2010 is on track to close out, as

- expected
  - -Approa about resear obliga
    - This were

- NCI's Executive Committee continues to prioritize funding decisions within budget constraints
- Weekly budget meetings track spending and keep NCI on track for a balanced budget at year's end
- EC traditionally holds a summer
  budget retreat; holding dates for new director

Preparing for the Fourth Quarter of FY 2010

- Current estimate for FY 2010 competing RPGs is \$496 million
  - Nearly \$40 million more than projected for FY 2010

Payline = 15th percentile

• We have set aside \$203 million for RFAs, which is \$70 million more than last year

### Planning NCI's space needs for the years ahead.



**Executive Plaza** 

## NCI Shady Grove



Selected after a rigorous, year long competitive bidding process conducted by the General Services Administration, in consultation with NIH and NCI


- 2 new custom-built, state-of-the-art buildings with 490,000 net square feet of usable space
- Able to accommodate ~2,400 staff members
- Leadership in Energy & Environmental Design (LEED) Silver Rating
- Move will take place in early 2013











# Meeting the increasing need for public-private partnerships.



NCI-Frederick, Bldg. 549

### Advanced Technology Research Facility


- 330,000 square foot facility will contain:
  - NCI's Biopharmaceutical Development Program manufacturing facility
  - NCI's Advanced Technology Program
  - Advanced Computing Program
  - Incubator Space for Initial Private Partnerships



### Advanced Technology Research Facility



### Most Drugs Fail in Late Stages of Development, Particularly in Oncology



Rates of success for compounds entering first-in-man that progress to subsequent phase trials


- 70% of oncology drugs that enter Phase 2 fail to enter Phase 3
- 59% of oncology drugs that enter Phase 3 fail
- Late stage failure leads to enormous risk
- Failure is more often due to lack of efficacy than to toxicity

# IOM Report


- "A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program"
  - Co-chairs: John Mendelsohn and Harold L.
  - "With many la trials system cumbersome needs to be read and improve move beyond academic, go

#### Four goals:

- Promote consolidation and efficiency
- Incorporate innovation in science and trial design
- Provide adequate funding and support
- Incentivize participation by patients and physicians



#### Changing the NCI's Clinical Trials System to Meet the Needs of the 21st Century



#### Our clinical trials system must reflect dramatic changes in cancer biology that occurred over the past 15-20 years

#### What do we need to change?

- Improve the speed and efficiency of the development and conduct of trials
- Incorporate innovative science and trial design into our studies
- Improve prioritization, support, and completion of trials
- Incentivize the participation of patients and physicians in clinical investigations


#### What have we changed?

- Resources for the development of predictive biomarkers
- Clinical trial prioritization
- Operational efficiency standards for trial development
- Regulatory & administrative support
- Modernized clinical trial IT infrastructure


#### Where do we go from here?

### NCI's Vision for Drug Development

- Implementing the "Dilts study" data to achieve clinical trial efficiencies
- Not intended to replicate Pharma
- Focus on bringing academic targets and molecules to patients
- Will not shy away from difficult targets
- Longer time horizon
- Valley of Death mitigating risk
- Pre-clinical research infrastructure for early "go-no go" decisions



#### NCI National Clinical Trials System





Merger of NCI drug and imaging agent development programs

- Integration of PD-Biomarkers Program
- Creation of Chemical Biology
  Consortium
- Development of Functional Biology Consortium


### Mission of the NCI Experimental Therapeutics (NExT) Program

"To advance clinical practice and **bring improved therapies to patients with cancer** by supporting the most promising new drug discovery and development projects."

"The NCI will partner with successful applicants to facilitate the milestone-driven progression of new anti-cancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration."

http://next.cancer.gov

### The NExT Pipeline



### NExT Application and Review Process

- 4 rounds annually; completed review of 3 cycles
- Cycle one: 52 applications received

- Discovery: 44 applications; 8 approved

- Development: 8 applications; 2 approved

• Cycle two NExT & RAID: 53 applications


-Discovery: 20 applications, 3 approved

- Development: 33 applications, 6 approved

• Cycle three NExT: 23 applications

-Discovery: 11 applications, 3 approved


- Development: 12 applications, 3 approved



### EC Scientific Retrea

"Making Personalized Cancer Medicine a Reality What Will It Take?"

> http://www.cancer.gov/ directorscorner



Functional biology

Phenotypes

• Cancer must be analyzed as a network of systems; not a tissue-specific disease state

- Cancer must be analyzed as a network of systems; not a tissue-specific disease state
- Multi-dimensional data sets will be the rule; we need new tools to analyze data that yield new insights

- Cancer must be analyzed as a network of systems; not a tissue-specific disease state
- Multi-dimensional data sets will be the rule; we need new tools to analyze data that yield new insights
- Drug and diagnostic development in an age of personalized medicine require a new business model

- Cancer must be analyzed as a network of systems; not a tissue-specific disease state
- Multi-dimensional data sets will be the rule; we need new tools to analyze data that yield new insights
- Drug and diagnostic development in an age of personalized medicine require a new business model
- Teamwork is critical, and barriers that impede teamwork need to be eliminated

 Resistance to change within the clinical and scientific cultures is impeding progress

- Resistance to change within the clinical and scientific cultures is impeding progress
- The field must embrace the complexity and heterogeneity of cancer

- Resistance to change within the clinical and scientific cultures is impeding progress
- The field must embrace the complexity and heterogeneity of cancer
- Nanotechnology is driving revolutionary advances and will open new avenues of research

### Messages from the EC Scientific Retreat

- Resistance to change within the clinical and scientific cultures is impeding progress
- The field must embrace the complexity and heterogeneity of cancer
- Nanotechnology is driving revolutionary advances and will open new avenues of research
- There is a critical need for better incentives for collaboration and tissue collection



 NCI's ability to form public-private partnerships, particularly around drug development



- NCI's ability to form public-private partnerships, particularly around drug development
- Reshaping clinical trials

# Challenges Ahead

- NCI's ability to form public-private partnerships, particularly around drug development
- Reshaping clinical trials
- Increasing the base, to maintain momentum created by ARRA

# Challenges Ahead

- NCI's ability to form public-private partnerships, particularly around drug development
- Reshaping clinical trials
- Increasing the base, to maintain momentum created by ARRA
- Fostering innovative, collaborative scientific initiatives




Preparing for the Fourth Quarter of FY 2010

- \$317 million of ARRA funds still to be obligated, or about 25 percent
  - -\$164 million in grants
  - -\$148 million in contracts



### Number of RPG Applications



## NCI's Investments

Despite below-inflation budgets, NCI has launched a number of important initiatives

- Chemical Biology Consortium
- Functional Biology Consortium
- Physical Sciences-Oncology Centers
- Coordinating Center for Clinical Trials
- BIG Health Consortium
- Target Discovery and Development Network
- Advanced Technology Partnership Initiative
- Cancer Human Biobank (caHUB)
- NCI Community Cancer Centers Program

If we ask ourselves... "Where is the optimal integration of molecular cancer science and clinical research being conducted?"

Single, national Cooperative Group trial structure?

### NCI Cancer Centers

- -Translational trials
- -Correlative science
- -SPOREs
- NCI Clinical Center Cancer Program
- Patient Characterization Centers

- NCI Community Cancer Centers Program
- Community Clinical Oncology Program
- National clinical trial patient cohort???

